Early Antihypertensive Efficacy of Olmesartan Medoxomil

Saito, Ikuo; Kushiro, Toshio; Ishikawa, Mayumi; Matsushita, Yasuyuki; Sagawa, Kei; Hiramatsu, Katsutoshi; Komiya, Masahiro

doi:10.1111/j.1751-7176.2008.00050.x

Cited by 7 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 There are substantial data showing the antihypertensive effects of OLM on CBP, but little data are available on HBP levels. 17, 18, 19, 20, 21, 22 …”

Section: Introductionmentioning

confidence: 99%

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study

et al. 2012

Self Cite

View full text Add to dashboard Cite

On the basis of the studies that investigated the relationship between baseline clinic blood pressure (CBP) or home blood pressure (HBP) values and cardiovascular (CV) events, HBP has been reported to have a stronger prognostic ability. However, few studies have compared the prognostic ability of on-treatment CBP and HBP. The relationship between on-treatment HBP, measured twice in the morning and twice at bedtime, and CV events was investigated in over 20 000 patients in the HONEST (Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure) Study, a prospective, 2-year observational study of treatment with an angiotensin receptor blocker, olmesartan (OLM), in OLM-naive hypertensive patients. This report summarizes the study protocol, the baseline characteristics of the patients and CBP and HBP at 16 weeks. A total of 22 373 patients were registered across Japan; baseline data from 22 162 patients were collected. Baseline HBP (mean±s.d.) in the morning (the first measurement) was 151.6±16.4/87.1±11.8 mm Hg and at bedtime was 144.3±16.8/82.8±11.9 mm Hg, whereas CBP was 153.6±19.0/87.1±13.4 mm Hg. At 16 weeks, morning HBP was 135.0±13.7/78.8±9.9 mm Hg and bedtime HBP was 129.7±13.8/74.7±10.1 mm Hg, whereas CBP was 135.6±15.4/77.6±10.9 mm Hg. The follow-up period for each patient ends on 30 September 2012. The HONEST Study is expected to provide evidence showing the relationship between baseline and on-treatment CBP and HBP levels (both first and second measurements) and CV events.

show abstract

“…16 There are substantial data showing the antihypertensive effects of OLM on CBP, but little data are available on HBP levels. 17, 18, 19, 20, 21, 22 …”

Section: Introductionmentioning

confidence: 99%

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings are supported by several clinical studies, including a recent secondary analysis of an open-label, prospective cohort study in Japan [15]. A total of 2221 patients received olmesartan as monotherapy (mainly at 10 mg and 20 mg doses) and their BP was determined within 3 weeks of initiating treatment.…”

Section: Article Highlightsmentioning

confidence: 77%

“…The mean BP was 147/85.6 mmHg (p < 0.0001) after 1 week in the early BP determination group (from a baseline level of 169.0/95.6 mmHg) and 146.5/84.7 mmHg (p < 0.0001) after 2 weeks in the standard BP determination group (from a baseline of 168.2/95.2 mmHg). The changes seen after 1 week in the early BP measurement group represent approximately 60 and 70% respectively of the SBP and DBP reductions seen at week 12 (31.6 and 16.7 mmHg, respectively) [15]. Such findings are supported by OLMEBEST, a large (n = 2306), multinational, multicenter study that investigated the efficacy of olmesartan 20 mg [16].…”

Section: Article Highlightsmentioning

confidence: 82%

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

Barrios¹,

Escobar²

2010

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Morning home BP decreased significantly after the first week of treatment. Saito et al 28 have reported that olmesartan is safe and effective in reducing clinic BP after 1 week of treatment.…”

Section: Discussionmentioning

confidence: 99%

Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks

et al. 2013

View full text Add to dashboard Cite

Morning home blood pressure (BP) levels are more closely associated with cardiovascular risk than clinic BP levels. However, control of morning home BP has been worse than that of clinic BP in clinical practice. We examined the effects of olmesartan-based treatment using data (n=21 341) from the first 16 weeks of the Home BP measurement with Olmesartan Naive patients to Establish Standard Target blood pressure (HONEST) study, a prospective observational study for olmesartan-naive patients with essential hypertension. After 16-week olmesartan-based treatment, the clinic and morning home systolic BP (SBP) lowered from 151.6±16.4 and 153.6±19.0 mm Hg to 135.0±13.7 and 135.5±13.7 mm Hg, respectively (P<0.0001). The achievement percentage of target morning home SBP (<135 mm Hg) in all patients, those with diabetes mellitus (DM), and those with chronic kidney disease (CKD) increased from 13.5, 16.4 and 17.2% to 50.8, 47.9 and 48.8%, respectively, and the proportion of patients with well-controlled hypertension (clinic SBP<140 mm Hg and morning home SBP<135 mm Hg) increased from 7.9, 9.2 and 10.2% to 38.9, 34.5 and 36.3%, respectively. After 16-week olmesartan-based treatment, the proportion of patients with masked and white coat hypertension changed from 11.8 to 24.2% and 5.6 to 11.9%. In conclusion, both clinic and morning home BP in all, DM and CKD patients improved with 16-week olmesartan-based treatment in the ‘real world', and the results showed a sustained 24-hour BP-lowering effect of olmesartan. Decrease in clinic and home BP resulted in an increased rate of masked and white coat hypertension, and further management is needed in those patients.

show abstract

Early Antihypertensive Efficacy of Olmesartan Medoxomil

Cited by 7 publications

References 21 publications

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks

Contact Info

Product

Resources

About